Skip to main content

Table 1 Baseline demographic and clinical features of patients with enterococcal bacteremia

From: Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species

   28-day all mortality
Characteristics Total (n = 37) Survivors (n = 29) Non-survivors (n = 8) P value
Demographics     
Age (year, mean±SD) 60.5 ± 13.2 62.8 ± 2.3 52.3 ± 4.4 0.044
BMI (mean±SD) 21.4 ± 3.1 21.2 ± 0.6 22.4 ± 1.1 0.323
Male (%) 22 (59.5) 18(62.1) 4(50.0) 0.412
Community AB (%) 9 (24.3) 7 (24.1) 2 (25.0) 0.643
Hospital AB (%) 28 (75.7) 22 (75.9) 6 (75.0) 0.643
Comorbidities (%)     
Solid cancer 21 (56.8) 17 (58.6) 4 (50.0) 0.483
HTN 15 (40.5) 11 (37.9) 4 (50.0) 0.412
DM 13 (35.1) 11 (37.9) 2 (25.0) 0.408
Chronic liver disease 11 (29.7) 8 (27.6) 3 (37.5) 0.444
Organ transplantation 9 (24.3) 7 (24.1) 2 (25.0) 0.643
Chronic renal disease 9 (24.3) 6 (20.7) 3 (37.5) 0.292
Cerebrovascular disease 7 (18.9) 6 (20.7) 1 (12.5) 0.521
Cardiovascular disease 6 (16.2) 5 (17.2) 1 (12.5) 0.613
Hematologic malignancies 4 (10.8) 3 (10.3) 1 (12.5) 0.640
CHF 3 (8.1) 2 (6.9) 1 (12.5) 0.530
Hemiplegia 2 (5.4) 2 (6.9) 0 (0.0) 0.610
PAOD 1 (2.7) 0 (0.0) 1 (12.5) 0.216
ILD 1 (2.7) 1 (3.4) 0 (0.0) 0.784
Antibiotic use in 30 day (%) 27 (73.0) 22 (75.9) 5 (62.5) 0.367
Steroid use in 30 day (%) 16 (43.2) 12 (41.4) 4 (50.0) 0.483
Anticancer drug use in 30 day (%) 9 (24.3) 7 (24.1) 2 (25.0) 0.643
Immunosuppressant use in 30 day (%) 9 (24.3) 7 (24.1) 2 (25.0) 0.643
Vancomycin induced AKI (%) 6 (16.2) 4 (13.8) 2 (25.0) 0.591
Septic shock (%) 8 (21.6) 4 (13.8) 4 (50.0) 0.049
Source of bacteremia (%)     
Biliary 15 (40.5) 12 (41.4) 3 (37.5) 0.588
Peritonitis 8 (21.6) 7 (24.1) 1 (12.5) 0.435
UTI 1 (2.7) 0 (0.0) 1 (12.5) 0.216
Skin 1 (2.7) 1 (3.4) 0 (0.0) 0.784
CRBSI 1 (2.7) 1 (3.4) 0 (0.0) 0.784
Foreign device 1 (2.7) 1 (3.4) 0 (0.0) 0.784
Others 2 (5.4) 1 (3.4) 1 (12.5) 0.390
Primary 8 (21.6) 6 (20.7) 2 (25.0) 0.565
ICU stay (%) 14 (37.8) 10 (34.5) 4 (50.0) 0.343
SOFA score (mean±SD) 7.0 ± 4.8 6.2 ± 0.8 9.9 ± 1.9 0.056
Persistent BSI (%) 18 (48.6) 15 (51.7) 3 (37.5) 0.379
Recurrence of same BSI (%) 5 (13.5) 5 (17.2) 0 (0.0) 0.272
Initial empirical inappropriate antibiotics (%) 16 (43.2) 13 (44.8) 3 (37.5) 0.517
Combination therapy (%) 8 (21.6) 6 (20.7) 2 (25.0) 0.565
PK/PD parameter (%)     
Trough level ≤15 µg/mL 19 (51.4) 12 (41.4) 7 (87.5)  
Trough level>15 µg/mL 18 (48.6) 17 (58.6) 1 (12.5) 0.042
AUC24/MIC≤389 7 (18.9) 5 (17.2) 2 (25.0)  
AUC24/MIC>389 30 (81.1) 24 (82.8) 6 (75.0) 0.479
BMI, body mass index; Community AB, Community acquired bacteremia; Hospital AB, Hospital acquired bacteremia; HTN, hypertension; DM, diabetes mellitus; CHF, congestive heart failure; PAOD peripheral arterial occlusive disease; ILD, interstitial lung disease; AKI. Acute kidney disease, UTI, urinary tract infection; CRBSI, catheter-related blood stream infection; BSI, blood stream infection, AUC, area under curve; MIC minimum inhibitory concentration; Other cases of bacteremia include infective endocarditis
Continuous variables are shown as the mean ± standard deviation (SD) and categorical variables, as numbers (percentage)